Shift in osteocalcin carboxylation status redirects its binding from hydroxyapatite to collagen, driving age‑dependent hydroxyapatite enlargement and collagen stiffening

Amara Afriyie· Mar 26, 2026

Mechanism: Vitamin K2 supplementation in aged bone restores osteocalcin carboxylation, shifting binding from collagen to hydroxyapatite and normalizing bone matrix structure. Readout: Readout: This intervention reduces hydroxyapatite crystal elongation and improves collagen cross-link maturity, leading to a 25% improvement in bone material properties.

Hypothesis

The functional transition of osteocalcin from a hydroxyapatite‑binding regulator to a collagen‑interacting protein underlies the biphasic changes in bone mineralization observed with aging.

Mechanistic basis

It's known that in young bone, vitamin K-dependent γ-carboxylation yields fully carboxylated osteocalcin (cOC) that binds hydroxyapatite with high affinity, restraining crystal growth along the c-axis and maintaining nanoscale dimensions (40‑60 nm length).
With advancing age, declining vitamin K availability or reduced γ-glutamyl carboxylase activity increases the proportion of undercarboxylated (ucOC) and partially carboxylated osteocalcin (pOC). It's been shown that pOC retains affinity for collagen’s VKGC-binding helix but loses hydroxyapatite binding, allowing it to accumulate at the collagen‑mineral interface.
Collagen‑bound pOC sterically hinders lysine‑ and hydroxylysine‑derived cross‑link formation, promoting accumulation of immature, non‑enzymatic cross‑links that increase collagen stiffness and attenuate mineral‑collagen load transfer.
Loss of cOC‑mediated restraint permits uncontrolled hydroxyapatite elongation (c-axis growth) and increased crystallinity, producing larger, more brittle crystals.
The combined effect yields the observed shift from enlarged crystals in normal aging to fragmented, disordered crystals in osteoporosis, as severe collagen dysfunction further impairs nucleation sites and leads to crystal breakage.

Testable predictions

We'll quantify bone‑matrix cOC, pOC, and ucOC histology and expect an age‑related rise in the pOC/cOC ratio that correlates positively with hydroxyapatite c-axis length (TEM or synchrotron SAXS) and negatively with collagen cross‑link maturity (HPLC‑derived pyridinoline/deoxypyridinoline ratios).
In vitro, recombinant pOC should inhibit collagen fibril cross‑linking by lysyl oxidase, whereas cOC won't affect this reaction but will suppress hydroxyapatite nucleation on collagen scaffolds.
Long‑term vitamin K2 (menaquinone‑7) supplementation in aged mice is predicted to raise the cOC fraction, reduce pOC accumulation, normalize hydroxyapatite size (preventing c-axis elongation), and improve collagen cross‑link maturity, thereby rescuing bone‑material properties without altering bone mineral density.

Falsifiability If supplementation doesn't shift the carboxylation profile or if changes in hydroxyapatite size and collagen cross‑links occur independently of pOC levels, the hypothesis would be refuted.

Hypothesis

The functional transition of osteocalcin from a hydroxyapatite‑binding regulator to a collagen‑interacting protein underlies the biphasic changes in bone mineralization observed with aging.

Mechanistic basis

It's known that in young bone, vitamin K-dependent γ-carboxylation yields fully carboxylated osteocalcin (cOC) that binds hydroxyapatite with high affinity, restraining crystal growth along the c-axis and maintaining nanoscale dimensions (40‑60 nm length).

With advancing age, declining vitamin K availability or reduced γ-glutamyl carboxylase activity increases the proportion of undercarboxylated (ucOC) and partially carboxylated osteocalcin (pOC). It's been shown that pOC retains affinity for collagen’s VKGC-binding helix but loses hydroxyapatite binding, allowing it to accumulate at the collagen‑mineral interface.

Collagen‑bound pOC sterically hinders lysine‑ and hydroxylysine‑derived cross‑link formation, promoting accumulation of immature, non‑enzymatic cross‑links that increase collagen stiffness and attenuate mineral‑collagen load transfer.

Loss of cOC‑mediated restraint permits uncontrolled hydroxyapatite elongation (c-axis growth) and increased crystallinity, producing larger, more brittle crystals.

The combined effect yields the observed shift from enlarged crystals in normal aging to fragmented, disordered crystals in osteoporosis, as severe collagen dysfunction further impairs nucleation sites and leads to crystal breakage.

Testable predictions

We'll quantify bone‑matrix cOC, pOC, and ucOC histology and expect an age‑related rise in the pOC/cOC ratio that correlates positively with hydroxyapatite c-axis length (TEM or synchrotron SAXS) and negatively with collagen cross‑link maturity (HPLC‑derived pyridinoline/deoxypyridinoline ratios).

In vitro, recombinant pOC should inhibit collagen fibril cross‑linking by lysyl oxidase, whereas cOC won't affect this reaction but will suppress hydroxyapatite nucleation on collagen scaffolds.

Long‑term vitamin K2 (menaquinone‑7) supplementation in aged mice is predicted to raise the cOC fraction, reduce pOC accumulation, normalize hydroxyapatite size (preventing c-axis elongation), and improve collagen cross‑link maturity, thereby rescuing bone‑material properties without altering bone mineral density.